GlycoMimetics, Inc. (NASDAQ:GLYC) Major Shareholder Public Equities L.P. Invus Sells 363,949 Shares

GlycoMimetics, Inc. (NASDAQ:GLYC) major shareholder Public Equities L.P. Invus sold 363,949 shares of the firm’s stock in a transaction that occurred on Monday, July 29th. The stock was sold at an average price of $0.24, for a total transaction of $87,347.76. Following the sale, the insider now owns 7,966,780 shares of the company’s stock, valued at $1,912,027.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Public Equities L.P. Invus also recently made the following trade(s):

• On Friday, July 26th, Public Equities L.P. Invus sold 258,335 shares of GlycoMimetics stock. The stock was sold at an average price of $0.24, for a total transaction of $62,000.40.

GlycoMimetics Stock Performance

Shares of NASDAQ:GLYC opened at $0.22 on Friday. The company has a market cap of $13.92 million, a PE ratio of -0.37 and a beta of 2.19. GlycoMimetics, Inc. has a 52 week low of $0.20 and a 52 week high of $3.53. The firm has a 50 day simple moving average of $0.27 and a 200 day simple moving average of $1.65.

GlycoMimetics (NASDAQ:GLYC) last issued its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.01). On average, equities analysts predict that GlycoMimetics, Inc. will post -0.61 earnings per share for the current year.

Institutional Investors Weigh In On GlycoMimetics

An institutional investor recently bought a new position in GlycoMimetics stock. Advisor OS LLC bought a new position in GlycoMimetics, Inc. (NASDAQ:GLYC) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 101,000 shares of the biotechnology company’s stock, valued at approximately $238,000. Advisor OS LLC owned approximately 0.16% of GlycoMimetics as of its most recent SEC filing. 75.19% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. StockNews.com assumed coverage on shares of GlycoMimetics in a report on Friday. They set a “sell” rating for the company. HC Wainwright restated a “neutral” rating on shares of GlycoMimetics in a report on Tuesday, June 4th. TD Cowen cut shares of GlycoMimetics from a “buy” rating to a “hold” rating in a report on Friday, July 26th. Finally, Capital One Financial downgraded shares of GlycoMimetics from an “overweight” rating to an “equal weight” rating in a research report on Monday, May 6th.

GlycoMimetics Company Profile

GlycoMimetics, Inc, a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML.